NCT03603145

Brief Summary

PICO: Population: Women with unwanted pregnancy having a medical abortion and fulfilling inclusion and without exclusion criteria and opting for IUC as post abortion contraception. The medical abortion will be carried out according to the Swedish national evidence based guidelines. Intervention: Randomized to insertion of IUC within 48 hours after medical abortion. Control: Randomized to insertion of IUC at the time of a follow-up visit scheduled 2 to 4 weeks after the abortion according to routine care. Objectives: Evaluation of use of IUC, feasibility, safety, compliance, and acceptability of immediate insertion of IUC 0 to 48 hours after medical abortion compared with delayed IUC insertion at 2 to 4 weeks post abortion. The primary outcome measure will be the use of IUC at 6 months in both groups evaluated by telephone calls/emails follow up. Time plan: Planning: -March 2018 Study start: May 2018 End of recruitment: April 2020 Last patient Last visit April 2021 Analysis: 2021 Report of primary outcome and Safety: 2021

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
720

participants targeted

Target at P75+ for phase_3

Timeline
Completed

Started Jan 2019

Longer than P75 for phase_3

Geographic Reach
1 country

6 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 25, 2018

Completed
3 months until next milestone

First Posted

Study publicly available on registry

July 27, 2018

Completed
6 months until next milestone

Study Start

First participant enrolled

January 16, 2019

Completed
5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2023

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2024

Completed
Last Updated

May 1, 2023

Status Verified

April 1, 2023

Enrollment Period

5 years

First QC Date

April 25, 2018

Last Update Submit

April 28, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • use of intrauterine contraception at 6 months post abortion

    use of intrauterine contraception at 6 months post abortion in both groups evaluated through follow up by telephone/email.

    6 months post abortion

Secondary Outcomes (13)

  • Difference in the proportion of women who successfully have the IUC inserted

    10 minutes after (attempted) insertion

  • Expulsion rate following insertion in both groups

    12 months post insertion

  • Continued use of IUC

    12 months post abortion

  • Ease of insertion

    10 minutes after (attempted) insertion

  • Pain at time of insertion assessed as millimeters on a 10cm long unmarked Visual Analogue Scale.

    10 minutes after (attempted) insertion

  • +8 more secondary outcomes

Study Arms (2)

Immediate insertion

EXPERIMENTAL

Randomized to insertion within 48 hours of medical abortion

Procedure: Immediate insertion

Standard Insertion

NO INTERVENTION

Insertion at 2-4 weeks post medical abortion

Interventions

Immediate insertion of intrauterine contraception within 48 hours of medical abortion

Immediate insertion

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • years and older,
  • eligible for medical abortion,
  • opting for post abortion IUC,
  • able and willing to comply with planned follow up.

You may not qualify if:

  • Contraindication for medical abortion or
  • Contraindication for IUC (contraindications may be present for LNG-IUSs but the woman may still choose a Cu-IUD and thereby enter the study),
  • inability to give informed consent.
  • Septic abortion
  • Known hypersensiblity/allergy to levonorgestrel or any of the substances added to the LNG-IUS
  • Known abnormal uterine cavity
  • Chorioamnionitis
  • Abortion associated bleeding \> 1000ml
  • Uterine atony postabortion
  • Placental retention
  • Therapeutic antibiotic treatment during abortion, (antibiotics used only as prophylaxis is accepted)
  • History of breast cancer

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (6)

Falun Hospital

Falun, Sweden

RECRUITING

Sahlgrenska Hospital

Gothenburg, Sweden

RECRUITING

Danderyd Hospital

Stockholm, 182 88, Sweden

RECRUITING

Karolinska University Hospital

Stockholm, Sweden

RECRUITING

South General Hospital

Stockholm, Sweden

RECRUITING

Uppsala Academiska Hospital

Uppsala, Sweden

RECRUITING

Related Publications (1)

  • Hogmark S, Envall N, Gemzell-Danielsson K, Kopp Kallner H. One-year follow up of contraceptive use and pregnancy rates after early medical abortion: Secondary outcomes from a randomized controlled trial of immediate post-abortion placement of intrauterine devices. Acta Obstet Gynecol Scand. 2023 Dec;102(12):1694-1702. doi: 10.1111/aogs.14662. Epub 2023 Aug 23.

MeSH Terms

Conditions

Contraception Behavior

Condition Hierarchy (Ancestors)

Reproductive BehaviorBehavior

Study Officials

  • Helena Kopp Kallner, MD, PhD

    Karolinska Institute, danderyd Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Helena Kopp Kallner, MD, PhD

CONTACT

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Randomized controlled open label
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate professor, senior consultant obstetrics and gynecology

Study Record Dates

First Submitted

April 25, 2018

First Posted

July 27, 2018

Study Start

January 16, 2019

Primary Completion

December 31, 2023

Study Completion

December 31, 2024

Last Updated

May 1, 2023

Record last verified: 2023-04

Locations